Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 3/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871396 | 0.89 | CASR (0.48) | CASRAOC3SLC22A1OPRM1L3MBTL1 | |
| SCHEMBL16871059 | 0.89 | CASR (0.48) | CASRAOC3SLC22A1OPRM1L3MBTL1 | |
| SCHEMBL11618158 | 0.85 | AOC3 (0.49) | CASRAOC3MTNR1AMTNR1BTAS1R3 | |
| SCHEMBL11618270 | 0.85 | AOC3 (0.51) | CASRAOC3MTNR1AMTNR1BL3MBTL1 | |
| SCHEMBL2359719 | 0.84 | AOC3 (0.47) | CASRAOC3MTNR1AMTNR1BSLC22A1 | |
| SCHEMBL2318103 | 0.84 | AOC3 (0.47) | CASRAOC3MTNR1AMTNR1BSLC22A1 | |
| SCHEMBL15474083 | 0.84 | AOC3 (0.47) | CASRAOC3MTNR1AMTNR1BSLC22A1 | |
| SCHEMBL16871235 | 0.84 | AOC3 (0.47) | CASRAOC3SLC22A1OPRM1L3MBTL1 | |
| SCHEMBL2176341 | 0.84 | AOC3 (0.47) | CASRAOC3SLC22A1OPRM1L3MBTL1 | |
| SCHEMBL15121380 | 0.84 | AOC3 (0.53) | CASRAOC3MTNR1AMTNR1BSLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791287-B2 | Process for the synthesis of tapentadol and intermediates thereof | EUTICALS S.P.A. (IT) | 2014-07-29 | — | — | US | disclosed |
| US-20130178644-A1 | PROCESS FOR THE SYNTHESIS OF TAPENTADOL AND INTERMEDIATES THEREOF | EUTICALS S.P.A. (IT) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178644-A1 | PROCESS FOR THE SYNTHESIS OF TAPENTADOL AND INTERMEDIATES THEREOF | TKT, CYP2D6, OPRK1 | CASR 4856/4885AOC3 371/4885MTNR1A 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.